Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
Stylized medical scribe tool silhouette

Jun 3, 2026

BBH health tech round-up: May 2026

In May 2026, significant advancements in health tech were reported, emphasizing the integration of AI and digital solutions across various NHS organizations, leading to notable improvements in efficiency and patient care.The certification of Tandem Health’s AI Medical Scribe marks a pivotal moment, as it becomes the first AI scribe in Europe to receive MDR Class IIa certification. This achievement complements the earlier certification of its Coding Assistant, reinforcing the company’s commitment
A medical device on a desk in a clinical office setting.

Jun 3, 2026

EU Commission drafts guidelines on classifying high-risk systems under the AI Act

The European Commission has released draft guidelines aimed at helping companies determine whether their AI-integrated medical devices qualify as high-risk under the EU's Artificial Intelligence Act.The guidelines will supplement existing regulations under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), rather than replace them. Nils Lölfing, an attorney specializing in AI, emphasized the importance of these guidelines in clarifying the classification process for A
A minimalist illustration of a light bulb and gear representing innovation and commercialization.

Jun 3, 2026

UCL ranked among Europe’s leading universities for research spinouts

UCL has made significant strides in research commercialization, achieving high rankings in the Royal Academy of Engineering’s Spotlight on Spinouts 2026 report. It is positioned third in the UK and seventh in Europe, showcasing its capability to transform groundbreaking research into impactful companies.The report emphasizes UCL's success, particularly through its commercialization arm, UCLB, in sectors like medicine, AI, and green energy. It provides a thorough analysis of the UK spinout landsc
A data center cable on a concrete surface with a construction site in the background.

Jun 3, 2026

Polar Data Centres raises €800 Million for AI infrastructure growth

Polar Data Centres has successfully secured €800 million to enhance its AI infrastructure capabilities through a significant bond offering, marking a pivotal moment for the company and the Nordic market.This financing initiative will not only refinance existing debts but also facilitate the construction of new AI-ready data centers across Europe, with operations expected to commence in 2026 and 2027. The bond offering attracted considerable interest from institutional investors, leading to an ov
A minimalist representation of a car and cloud, illustrating automotive connectivity.

Jun 3, 2026

Vodafone Business expands partnership with Geely Technology Europe

Vodafone Business has announced an expansion of its collaboration with Geely Technology Europe (GTEU), focusing on advanced connectivity solutions for the automotive sector.The partnership now encompasses services such as Internet in the Car, mobile private networks, and cloud connectivity. The Internet in the Car service is designed to facilitate diagnostics and over-the-air software updates, enhancing vehicle performance and user experience. Meanwhile, the Cloud Connect feature allows for seam
A minimalist representation of a drug compound molecule in flat design.

Jun 3, 2026

Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026 - News and Statistics

The competition between Recursion Pharmaceuticals and Schrodinger highlights distinct drug discovery strategies as they leverage technology and data in their operations.Recursion Pharmaceuticals focuses on mechanizing drug discovery through artificial intelligence and extensive data analysis within the biotech sector. The company collaborates with major industry players like Roche and Bayer, relying heavily on their partnerships for revenue. Despite reporting a revenue increase of 26.9% to appro
Close-up of a respiratory device in a clinical setting

Jun 2, 2026

RMD: Strong growth, innovation, and digital health expansion position the company for continued leadership

ResMed Inc. is poised for ongoing leadership in the healthcare sector due to its impressive financial performance and innovative strategies.The recent conference showcased ResMed's significant financial growth, underscoring a solid pipeline of innovation. The company is strategically expanding into related markets, such as respiratory life sciences (RLS), which enhances its market reach and capabilities. Furthermore, advancements in digital health and the development of AI-driven products are ce
Silhouette of a document with a checkmark representing regulatory compliance

Jun 2, 2026

Pharma in Focus: The Regulatory Issues Everyone is Talking About

The increasing scrutiny of artificial intelligence (AI) by the FDA is prompting life science companies to enhance their regulatory compliance and quality oversight for AI tools in manufacturing. The inaugural session of "Pharma in Focus: The Regulatory Issues Everyone is Talking About" will delve into these challenges, centering around a case study of the FDA Warning Letter issued to Purolea, which highlights critical regulatory expectations.During this session, experts will discuss how the FDA'
A supercomputer in a research lab with NVIDIA GPUs

Jun 2, 2026

Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia

The integration of artificial intelligence (AI) within the pharmaceutical industry is rapidly evolving, yet the gap between investment and tangible outcomes remains significant, particularly in Asia.Recent developments highlight the growing conviction that AI is essential infrastructure in drug research and development. For instance, Eli Lilly's launch of the "LillyPod," a supercomputer equipped with over 1,000 NVIDIA GPUs, symbolizes this trend. However, despite such advancements, the company a
A minimalist illustration of a pill and stock chart

Jun 2, 2026

A Look At Recursion Pharmaceuticals (RXRX) Valuation As Shares Show Short Term Momentum

Recursion Pharmaceuticals (RXRX) is experiencing renewed investor interest, closing recently at $3.79. Despite a significant revenue of $66.41 million, the company reported a net loss of $559.78 million, leading to a market valuation of approximately $1.91 billion. The stock has shown short-term momentum with a 25.91% increase over the past week and an 11.80% rise over the last month, contrasting with a year-to-date decline of 9.76%.Current market sentiment suggests that RXRX is perceived as ove
A mass spectrometer in a laboratory setting

Jun 2, 2026

What Danaher (DHR)'s New AI-Enabled SCIEX Mass Spec Platform Means For Shareholders

Danaher’s recent upgrades to its SCIEX mass spectrometry platform signal a strategic move towards enhancing its market position in life sciences through AI integration.SCIEX, a subsidiary of Danaher, has introduced significant enhancements to its ZenoTOF line and launched the novus V55 triple quadrupole mass spectrometer, both powered by the new AI-enabled SCIEX OS 5.0 software. These advancements aim to optimize complex laboratory workflows and improve sensitivity, thereby bolstering Danaher's
A minimalist illustration of a microbe and abstract cells in a dark palette.

Jun 2, 2026

Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference

Zealand Pharma is set to engage in discussions at the upcoming Goldman Sachs Global Healthcare Conference, highlighting its commitment to advancing metabolic health solutions.On June 9, 2026, Adam Steensberg, the CEO of Zealand Pharma, will participate in a fireside chat during the 47th Annual Global Healthcare Conference in Miami. This event will be accessible via a live audio webcast, allowing stakeholders to tune in and gain insights into the company's strategic direction and innovations in m